NCT06475729

A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

A Bioequivalence Study of Subcutaneous Injections of Citrate-Free Mirikizumab Solution Using a 1-mL Autoinjector and an Investigational 2-mL Autoinjector in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 498 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector. Screening is required within 35 days prior to enrollment. For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Citrate-Free Mirikizumab	Administered SC

Timeline

• Start date: 2024-06-24
• Primary completion: 2024-12-27
• Completion: 2024-12-27
• First posted: 2024-06-26
• Last updated: 2025-12-30
• Results posted: 2025-12-30

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study